Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial